AIM ImmunoTech Secures $2.65M in At-Market Financing
Event summary
- AIM ImmunoTech raised $2.65M through a registered direct offering and concurrent private placement, priced at $0.5189 per share.
- The offering includes 2,554,119 registered shares and an equal number of unregistered shares or pre-funded warrants.
- Proceeds will fund clinical drug manufacturing, ongoing and planned Phase 3 trials, and working capital.
- The offering is expected to close on June 10, 2026, subject to customary closing conditions.
The big picture
AIM ImmunoTech's $2.65M raise underscores the ongoing challenge of funding late-stage immuno-oncology trials. The financing comes as biotech firms increasingly rely on at-market offerings to extend runway, reflecting tighter capital conditions. The strategic focus on Ampligen's clinical pipeline highlights the high-stakes nature of developing first-in-class immunotherapies.
What we're watching
- Clinical Progress
- The pace at which AIM ImmunoTech advances its Phase 3 trials will determine the utility of these funds.
- Market Conditions
- Whether the company can sustain investor interest amid volatile biotech financing markets.
- Regulatory Approvals
- How quickly Ampligen gains regulatory traction for its broad-spectrum applications.